Thursday, May 08, 2025 2:23:59 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent ALLO News
- Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock • GlobeNewswire Inc. • 04/16/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:35:50 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/15/2026 08:33:15 PM
- Allogene Publishes Promising ALLO-329 Data in Nature Communications • IH Market News • 04/15/2026 02:59:55 PM
- Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases • GlobeNewswire Inc. • 04/15/2026 12:30:00 PM
- Allogene Therapeutics Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 04/15/2026 01:50:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/13/2026 08:44:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 08:09:04 PM
- Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock • GlobeNewswire Inc. • 04/13/2026 08:01:00 PM
- Allogene shares jump on encouraging ALPHA3 trial update • IH Market News • 04/13/2026 02:13:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 11:45:15 AM
- Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL • GlobeNewswire Inc. • 04/13/2026 11:30:00 AM
- Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 • GlobeNewswire Inc. • 04/10/2026 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:47:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 11:13:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:06:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 12:20:12 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:36:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:11:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:07:14 PM
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 03/12/2026 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:42:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 02:04:36 AM
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update • GlobeNewswire Inc. • 03/02/2026 01:30:00 PM
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/05/2026 01:30:00 PM

